CKBR-12 for Parkinson’s
CKBR-12, an Ibogaine derivative medicine developed by Phytostan Pharmaceuticals is currently being investigated and used exclusively by Genesis as a medication to treat Parkinson’s disease (PD). It has been found to upregulate glial cell line-derived neurotrophic factor (GDNF) expression in the mid brain and increase GDNF secretion 6 and may represent a powerful new method to upregulate GDNF in the treatment of PD and other neurodegenerative disorders.
REDUCTION OF PD SYMPTOMS In Patients With CKBR-12
1. Decreased or elimination of Saliva and drooling. No problems in swallowing
2. Loss of any depression or anxiety.
3. Improvement in his speech, diction, and tongue control.
4. Increased facial activity, muscles coming alive. Loss of facial rigidity.
5. Regaining hand movement and use.
6. Free flowing handwriting.
7. Motor Skills: 50% or 75% better within 30 days.
8. Return of self dressing and dexterity with fingers
9. Naturally eating, cutting own food, don’t need assistance. Able to hold a fork and knife differently .
10. Balance: Standing up for long periods of time and regaining a sense of balance. Loss of feeling of falling.
11. Walking: Able to walk up and down stairs much faster and longer distances.
12. Loss of tremors.
One reason Ibogaine is so interesting is that it increases levels of glial cell line-derived neurotrophic factor (GDNF) in the brain (He & Ron 2006), and this in turn appears to be a potent survival factor for several different neuronal populations in different brain regions (Boscia et al. 2009) and has neuroprotective properties that promote the survival of both dopaminergic and motor neurons (Bermingham et al. 2004; He and Ron 2006), which may be one of the reasons for the prolonged afterglow often experienced following treatment with the drug. Furthermore, GDNF can cause sprouting of dopaminergic fibers and clinical improvement in experimental animal models of Parkinson’s disease, as well as a similar sprouting of dopaminergic fibers in humans with the disease, with the resultant clinical improvement in symptoms (Love et al. 2005). GDNF has also been identified as having anti-addictive properties (Ron & Janak 2005; Carnicella & Ron 2008.) This may be one of the reasons for Ibogaine’s effectiveness in treating drug addicts with impaired receptor function, but this drug may also be a considerable ally to those with degenerative neurological diseases.
Ibogaine increases levels of glial cell line-derived neurotrophic factor (GDNF) in the brain (He & Ron 2006), and this appears to have neuroprotective properties that promote the survival of both dopaminergic and motor neurons (Bermingham et al. 2004; He and Ron 2006). GDNF can also cause sprouting of dopaminergic fibers and clinical improvement in experimental animal and human studies in which the test subjects had Parkinson’s Disease, with the resultant clinical improvement in symptoms (Love et al. 2005). GDNF has been shown to have potent neurotrophic factor in Parkinson’s disease (Gill et al. 2003). Direct brain infusion of GDNF into the brains of five Parkinson sufferers resulted in a 39% improvement in the off-medication motor sub-score of the Unite Parkinson’s Disease Rating Scale (UPDRS) and a 61% improvement in the activities of daily living sub score (Gill et al. 2003). Positron emission tomography (PET) scans of dopamine uptake showed a significant 28% increase in putamen dopamine storage after 18 months, indicating a direct effect of GDNF on dopamine function. Furthermore, after one year, no serious clinical side effects were observed (Gill et al. 2003).
Both Parkinson’s disease, motor neuron disease and Alzheimer’s Disease are chronic disorders with no known cure. Most neurodegenerative diseases require management with prescription medications that can have considerable side effects, which may cause a very poor quality of life for terminal sufferers. In turn, Ibogaine may be very beneficial to those with degenerative neurological diseases.
The use of Ibogaine would provide a longer term and much less invasive method of GDNF administration than direct brain infusion. Ibogaine therapy offers a non-invasive and low-toxicity method of treatment for sufferers of this disease.